ZVRA

BOSTON, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc.

Presentations from U.S. and German early access programs highlight sustained disease stabilization and a consistent safety profile across diverse NPC patient populations Presentations from U.S.

BOSTON, Mass., Aug. 21, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc.

Zevra Therapeutics (NasdaqGS:ZVRA) reported new long term real world safety and effectiveness data for arimoclomol in adults with Niemann Pick disease type C.

Zevra Therapeutics (NASDAQ:ZVRA) reported second-quarter 2026 net revenue of $39.7 million, up 53% from $25.9 million a year earlier, driven primarily by U.S. sales of its Niemann-Pick disease type C treatment MIPLYFFA. Net U.S.

Zevra Therapeutics Inc (ZVRA) posts strong Q2 2026 results with $39.7 million in revenue and net income of $8.8 million, while navigating EU regulatory challenges for arimoclomol.

Zevra Therapeutics (ZVRA) delivered earnings and revenue surprises of +212.50% and +22.76%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

BOSTON, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc.

Longitudinal study includes first published real-world data on arimoclomol in adults with NPC and provides insights across a broad patient populationBOSTON, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc.

On Friday, Zevra announced that the EMA’s Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion on its application to market arimoclomol for Niemann-Pick disease type C.

The company plans to seek a re-examination after the European regulator’s advisory committee issued a negative opinion on arimoclomol for Niemann-Pick disease type C.